Page 28 - 51 the significance--29.2_opt

81. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology,
pathophysiology, and management. JAMA 2002;287(19):2570-81.
82. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart
disease in subjects with type 2 diabetes and in nondiabetic subjects with and without
prior myocardial infarction. The New England journal of medicine 1998;339(4):229-34.
83. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial
intervention and cardiovascular disease in patients with type 2 diabetes. The New
England journal of medicine 2003;348(5):383-93.
84. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and
prevention. J Intern Med 2001;249(3):225-35.
85. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes
care 2003;26(3):917-32.
86. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive
diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control
and Complications Trial/Epidemiology of Diabetes Interventions and Complications
study. Diabetes care 2007;30(8):2107-12.
87. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., et al. A definition
of advanced types of atherosclerotic lesions and a histological classification of
atherosclerosis. A report from the Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association. Circulation 1995;92(5):1355-74.

28